ArticleFrontiers in pharmacology2022

LY2874455 and Abemaciclib Reverse FGF3/4/19/CCND1 Amplification Mediated Gefitinib Resistance in NSCLC.

Dongcheng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.